Consistent with the results in non-tumor-bearing animals, KISIMA-HPV prime followed by VSV-GP-HPV boost resulted in significantly higher frequency (Fig. 2b) and absolute numbers (Fig. 2c) of HPV-E7-specific CD8+ T cells in the periphery, compared to homologous VSV-GP-HPV treatment. The gene discussed is CD8A; the disease is neoplasm.